Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
gptkb:J05AX17
|
| gptkbp:chemicalFormula |
C29H28F4N4O4
|
| gptkbp:drugClass |
antiviral
|
| gptkbp:genericName |
letermovir
|
| https://www.w3.org/2000/01/rdf-schema#label |
Prevymis
|
| gptkbp:indication |
prevention of cytomegalovirus (CMV) infection
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:mechanismOfAction |
inhibits CMV DNA terminase complex
|
| gptkbp:pregnancyCategory |
Not assigned (consult physician)
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
diarrhea fatigue cough |
| gptkbp:usedIn |
hematopoietic stem cell transplant recipients
|
| gptkbp:bfsParent |
gptkb:Letermovir
|
| gptkbp:bfsLayer |
7
|